Browse Category: Medical > Therapeutics


[Search within category]

Compositions for Enhancing Beta Cell Maturation, Health, and Function

Beta cell failure is the central cause of type-2 diabetes. Researchers at UCI have developed molecules for treating diabetes that target proteins on the surface of beta cells and induce their clustering. This clustering results in an increase in insulin secretion and content and promotion of beta cell maturation. Furthermore, the clustering effect seen with these compositions may promote both proliferation and the reversal of de-differentiation.

An Endogenous Anti-angiogenic Protein (EAP) and its Derivatives for Treatment of Cerebral Cavernous Malformations (CCM)

Cerebral cavernous malformation (CCM) is a neurovascular disease that causes epilepsy and stroke for which there is no medical therapy. It has a prevalence of 5 per thousand in western populations and occurs in familial forms as a consequence of mutations in 3 CCM genes: CCM1/KRIT1, CCM2, CCM3/PCDC10 resulting in the formation of CCMs; mutations in the CCM1/KRIT1 gene account for 40% of the inherited cases. Once identified, CCM patients have a lifetime risk of CCM development and progression with increasing risk of stroke, epilepsy, or neurological impairment. 

New Pathway For Cancer Therapy

The field of oncology has seen dramatic increases in understanding in recent years, but new pathways relevant to cancer biology offer opportunities for the screening of small molecules.

Small Molecule Antagonists Of The Pro-Survival Protein Mcl-1

UCLA Researchers have discovered novel inhibitors to signaling proteins involved in the regulation of apoptosis. MCL-1, which is known to be overexpressed in many cancers, is believed to be upregulated in cancers to prevent the apoptosis pathway.The researchers have developed novel small molecules that inhibit this protein, triggering apoptosis and cancer cell death.

Culturing More Mature iPSC-derived Cardiac Myocytes

Researchers at the University of California, Davis have developed a non-genetic, non-pharmacological method for culturing more mature induced pluripotent stem cell-derived cardiac myocytes.

A Synthetic Peptide for Use in Diagnosis and Treatment of Myasthenia Gravis

Researchers at the University of California, Davis have developed a peptide that could be used in the diagnosis and treatment of Myasthenia Gravis.

Wireless Implantable System To Restore Memory

UCLA researchers have developed a wireless implantable deep brain stimulation system to restore memory in individuals with traumatic brain injury.

Small Molecule Generation of Multinucleated and Striated Myofibers from Human Pluripotent Stem Cells Equivalent to Adult Skeletal Muscle

Researchers in the UCLA Department of Microbiology, Immunology and Molecular Genetics have developed a novel means of generating adult skeletal muscle-equivalent myofibers from human pluripotent stem cells.

CRISPR/Cas9 Mediated Genome Editing For Duchenne Muscular Dystrophy

UCLA researchers in the Department of Microbiology, Immunology & Molecular Genetics have developed a method to permanently correct the out-of-frame dystrophin gene in patient cell models of Duchenne Muscular Dystrophy (DMD)

Stem Cell Therapy For Dysphagia Due To Tongue Atrophy

UCLA researchers have developed a novel method to treat dysphagia due to tongue atrophy via the transplantation of multipotent or differentiated stem cells.

Biomarkers Of Response And Synergistic Combinations With ERK Targeted Therapies In Human Cancers

UCLA researchers have identified a set of genomic markets that identify a group of human cancer cell lines more likely to respond to ERK1/2 inhibitors. These markers are believed to be critical in identifying those patients that will most likely respond to ERK1/2 inhibition used in cancer therapy.

Biomarkers Of Response To Cyclin D - CDK4/6 Targeted Therapies In Human Cancers

UCLA researchers have identified 9 genetic response markers that may play a mechanistic role in determining sensitivity or resistance to treatment with the CDK-4/6 and cyclin D inhibitors.

Biomarkers Of Response To Inhibition Of Poly-Adp Ribose Polymerase (PARP) In Human Cancers

The Slamon and Finn groups at UCLA have discovered that specific chromosomal gains can serve as biomarkers that predict a cancer patient response to treatments that use poly-ADP ribose polymerase (PARP) inhibitors.

Methods And Device For Use Of Phase Locked High Frequency Oscillations To Distinguish The Epileptogenic Ictal Core

UCLA researchers have developed a method and device for the automatic identification of phase-locked high-frequency oscillations to localize epileptogenic brain for neurological intervention.

Novel therapeutic approach for obesity: Pharmacological targeting of Kv1 potassium channels

Obesity is a global epidemic that is in need of novel and safe therapeutics. Despite the enormous efforts by pharmaceutical companies, there is a shortage for safe therapeutics for obesity. Researchers at UCI have developed a selective inhibitor of Kv1.3 potassium channel, ShK-186, which displays powerful anti-obesity effects in a mouse model of diet-induced obesity. Using critical experimental measures, researchers highlight the potential use of Kv1.3 blockers in the treatment of obesity and insulin resistance.

New Compounds For The Treatment Of Diseases Related To Protein Misfolding

UCLA researchers in the Department of Neurology with an international team of scientists have developed compounds for therapeutic use in protein misfolding diseases.

Thrombospondins as a target to treat neuropathic pain

Neuropathic pain is a common problem, though, there are few existing pain medications have specific targets to treat this type of pain, and often lack efficacy and tolerance. The invention identifies specific proteins and related genes as targets for treating neuropathic pain in an animal model.

ShK-K22DAP, an immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of T-cells

Blocking of potassium channels in T cells is a promising therapeutic approach for treatment of chronic autoimmune diseases. Researchers at UCI have developed a potent peptide inhibitor of potassium channels that has high affinity and is >100 fold selective to a specific potassium channel, Kvl.3, over others.

Stimuli Responsive Immunostimulants

An immune response typically occurs during inflammation, auto-immune diseases, or cancers. In such cases, chemical triggers, or immunostimulants, recognized by receptor proteins at cell membranes activate the immune cells. Researchers can use these immunostimulants to test how different cell subsets contribute to immune response mechanisms. This invention describes a novel type of immunostimulant that can be toggled on and off, both inside the body and in vitro.

Ligands for Improved Angiogenesis and Endothelialization of Blood Contacting Devices

Researchers at the University of California, Davis have discovered novel targeting ligands that can specifically bind and capture endothelial cells and endothelial progenitors for improved endothelialization and angiogenesis of medical devices and scaffolds.

Re-Sensitizing Cancer Cells to Anticancer Drugs

Researchers at the University of California, Davis have discovered a new class of ROR-γ inhibitors which can reduce and reverse cancer cell resistance to anticancer drugs.

Novel Solid Tumor Chemodrug LLS2

Researchers at the University of California, Davis have developed a new library of small molecule LLS2 that can kill a variety of cancer cells

Mi-181: A Potent Small Synthetic Microtubule-Targeting Anticancer Agent

UCLA researchers in the Department of Chemistry & Biochemistry and Department of Molecular & Medical Pharmacology have discovered compound MI-181 and successfully synthesized its derivatives and analogs, which have the potential for use in cancer therapy by arresting cells during the process of cell division and promoting apoptosis.

Therapeutic strategies for Huntington’s Disease using stop codon suppression

In Huntington’s Disease (HD), aberrant splicing of the huntingtin protein can produce a highly toxic peptide that accumulates in the brain. The invention describes methods to minimize the toxicity of spliced proteins.

Antibodies targeting mammalian Sterol Regulatory Element Binding Proteins (SREBP) 1 and 2

Sterol Regulatory Element Binding Proteins (SREBP) are important factors that control lipid homeostasis in mammals. Researchers at UCI have prepared antibodies that have good affinity and specificity for human SREBP1/2 for use as research tools. These antibodies have application in genetic and immunotherapeutic research areas.

  • Go to Page: